Takeda Interest Debt Per Share from 2010 to 2025

TAK Stock  USD 15.02  0.02  0.13%   
Takeda Pharmaceutical Interest Debt Per Share yearly trend continues to be quite stable with very little volatility. Interest Debt Per Share may rise above 3,019 this year. From the period between 2010 and 2025, Takeda Pharmaceutical, Interest Debt Per Share regression line of its data series had standard deviation of  1,405 and standard deviation of  1,405. View All Fundamentals
 
Interest Debt Per Share  
First Reported
2010-12-31
Previous Quarter
2.9 K
Current Value
K
Quarterly Volatility
1.4 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Takeda Pharmaceutical financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Takeda Pharmaceutical's main balance sheet or income statement drivers, such as Depreciation And Amortization of 879.1 B, Interest Expense of 185.5 B or Selling General Administrative of 783 B, as well as many indicators such as Price To Sales Ratio of 1.67, Dividend Yield of 0.0417 or PTB Ratio of 0.98. Takeda financial statements analysis is a perfect complement when working with Takeda Pharmaceutical Valuation or Volatility modules.
  
Check out the analysis of Takeda Pharmaceutical Correlation against competitors.

Latest Takeda Pharmaceutical's Interest Debt Per Share Growth Pattern

Below is the plot of the Interest Debt Per Share of Takeda Pharmaceutical Co over the last few years. It is Takeda Pharmaceutical's Interest Debt Per Share historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Takeda Pharmaceutical's overall financial position and show how it may be relating to other accounts over time.
Interest Debt Per Share10 Years Trend
Slightly volatile
   Interest Debt Per Share   
       Timeline  

Takeda Interest Debt Per Share Regression Statistics

Arithmetic Mean1,800
Geometric Mean991.73
Coefficient Of Variation78.05
Mean Deviation1,339
Median2,875
Standard Deviation1,405
Sample Variance2M
Range3.7K
R-Value0.85
Mean Square Error575,935
R-Squared0.73
Significance0.000027
Slope251.66
Total Sum of Squares29.6M

Takeda Interest Debt Per Share History

2025 3018.65
2024 2874.9
2023 3194.34
2022 2933.38
2021 2885.84
2020 3126.75
2019 3376.76

About Takeda Pharmaceutical Financial Statements

Takeda Pharmaceutical investors utilize fundamental indicators, such as Interest Debt Per Share, to predict how Takeda Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Interest Debt Per Share2.9 KK

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Takeda Pharmaceutical is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Takeda Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Takeda Pharmaceutical Co Stock. Highlighted below are key reports to facilitate an investment decision about Takeda Pharmaceutical Co Stock:
Check out the analysis of Takeda Pharmaceutical Correlation against competitors.
You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Takeda Pharmaceutical. If investors know Takeda will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Takeda Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.78)
Dividend Share
192
Earnings Share
0.43
Revenue Per Share
1.5 K
Quarterly Revenue Growth
0.03
The market value of Takeda Pharmaceutical is measured differently than its book value, which is the value of Takeda that is recorded on the company's balance sheet. Investors also form their own opinion of Takeda Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Takeda Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Takeda Pharmaceutical's market value can be influenced by many factors that don't directly affect Takeda Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Takeda Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Takeda Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Takeda Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.